147 related articles for article (PubMed ID: 37421840)
1. Prospectives of mirna gene signaling pathway in triple-negative breast cancer.
Chakkaravarthi K; Ramesh R; Palaniyandi T; Baskar G; Viswanathan S; Wahab MRA; Surendran H; Ravi M; Sivaji A
Pathol Res Pract; 2023 Aug; 248():154658. PubMed ID: 37421840
[TBL] [Abstract][Full Text] [Related]
2. MicroRNA profiling implies new markers of chemoresistance of triple-negative breast cancer.
Ouyang M; Li Y; Ye S; Ma J; Lu L; Lv W; Chang G; Li X; Li Q; Wang S; Wang W
PLoS One; 2014; 9(5):e96228. PubMed ID: 24788655
[TBL] [Abstract][Full Text] [Related]
3. Tumor tissue microRNA expression in association with triple-negative breast cancer outcomes.
Liu Y; Cai Q; Bao PP; Su Y; Cai H; Wu J; Ye F; Guo X; Zheng W; Zheng Y; Shu XO
Breast Cancer Res Treat; 2015 Jul; 152(1):183-191. PubMed ID: 26062749
[TBL] [Abstract][Full Text] [Related]
4. Identification of the Novel Tumor Suppressor Role of FOCAD/miR-491-5p to Inhibit Cancer Stemness, Drug Resistance and Metastasis via Regulating RABIF/MMP Signaling in Triple Negative Breast Cancer.
Huang WC; Chi HC; Tung SL; Chen PM; Shih YC; Huang YC; Chu PY
Cells; 2021 Sep; 10(10):. PubMed ID: 34685504
[TBL] [Abstract][Full Text] [Related]
5. Dual regulation by microRNA-200b-3p and microRNA-200b-5p in the inhibition of epithelial-to-mesenchymal transition in triple-negative breast cancer.
Rhodes LV; Martin EC; Segar HC; Miller DF; Buechlein A; Rusch DB; Nephew KP; Burow ME; Collins-Burow BM
Oncotarget; 2015 Jun; 6(18):16638-52. PubMed ID: 26062653
[TBL] [Abstract][Full Text] [Related]
6. Clinical Identification of Dysregulated Circulating microRNAs and Their Implication in Drug Response in Triple Negative Breast Cancer (TNBC) by Target Gene Network and Meta-Analysis.
Qattan A; Al-Tweigeri T; Alkhayal W; Suleman K; Tulbah A; Amer S
Genes (Basel); 2021 Apr; 12(4):. PubMed ID: 33918859
[TBL] [Abstract][Full Text] [Related]
7. Epithelial to mesenchymal transition and microRNA expression are associated with spindle and apocrine cell morphology in triple-negative breast cancer.
Koleckova M; Ehrmann J; Bouchal J; Janikova M; Brisudova A; Srovnal J; Staffova K; Svoboda M; Slaby O; Radova L; Vomackova K; Melichar B; Veverkova L; Kolar Z
Sci Rep; 2021 Mar; 11(1):5145. PubMed ID: 33664322
[TBL] [Abstract][Full Text] [Related]
8. MicroRNA-455-3p promotes invasion and migration in triple negative breast cancer by targeting tumor suppressor EI24.
Li Z; Meng Q; Pan A; Wu X; Cui J; Wang Y; Li L
Oncotarget; 2017 Mar; 8(12):19455-19466. PubMed ID: 28038450
[TBL] [Abstract][Full Text] [Related]
9. Racial differences in RAD51 expression are regulated by miRNA-214-5P and its inhibition synergizes with olaparib in triple-negative breast cancer.
Mani C; Acharya G; Saamarthy K; Ochola D; Mereddy S; Pruitt K; Manne U; Palle K
Breast Cancer Res; 2023 Apr; 25(1):44. PubMed ID: 37081516
[TBL] [Abstract][Full Text] [Related]
10. Differential expression of the miR-17-92 cluster and miR-17 family in breast cancer according to tumor type; results from the Norwegian Women and Cancer (NOWAC) study.
Moi L; Braaten T; Al-Shibli K; Lund E; Busund LR
J Transl Med; 2019 Oct; 17(1):334. PubMed ID: 31581940
[TBL] [Abstract][Full Text] [Related]
11. Meta-microRNA Biomarker Signatures to Classify Breast Cancer Subtypes.
Oztemur Islakoglu Y; Noyan S; Aydos A; Gur Dedeoglu B
OMICS; 2018 Nov; 22(11):709-716. PubMed ID: 30388053
[TBL] [Abstract][Full Text] [Related]
12. MicroRNA profiling identifies Forkhead box transcription factor M1 (FOXM1) regulated miR-186 and miR-200b alterations in triple negative breast cancer.
Hamurcu Z; Sener EF; Taheri S; Nalbantoglu U; Kokcu ND; Tahtasakal R; Cınar V; Guler A; Ozkul Y; Dönmez-Altuntas H; Ozpolat B
Cell Signal; 2021 Jul; 83():109979. PubMed ID: 33744419
[TBL] [Abstract][Full Text] [Related]
13. Novel prognostic and predictive microRNA targets for triple-negative breast cancer.
Turashvili G; Lightbody ED; Tyryshkin K; SenGupta SK; Elliott BE; Madarnas Y; Ghaffari A; Day A; Nicol CJB
FASEB J; 2018 May; ():fj201800120R. PubMed ID: 29812973
[TBL] [Abstract][Full Text] [Related]
14. Screening protective miRNAs and constructing novel lncRNAs/miRNAs/mRNAs networks and prognostic models for triple-negative breast cancer.
Zhao Y; Song Y; Zhang Y; Ji M; Hou P; Sui F
Mol Cell Probes; 2023 Dec; 72():101940. PubMed ID: 37871689
[TBL] [Abstract][Full Text] [Related]
15. Circulating cell-free miRNAs as biomarker for triple-negative breast cancer.
Shin VY; Siu JM; Cheuk I; Ng EK; Kwong A
Br J Cancer; 2015 May; 112(11):1751-9. PubMed ID: 25906045
[TBL] [Abstract][Full Text] [Related]
16. miR-105/93-3p promotes chemoresistance and circulating miR-105/93-3p acts as a diagnostic biomarker for triple negative breast cancer.
Li HY; Liang JL; Kuo YL; Lee HH; Calkins MJ; Chang HT; Lin FC; Chen YC; Hsu TI; Hsiao M; Ger LP; Lu PJ
Breast Cancer Res; 2017 Dec; 19(1):133. PubMed ID: 29258605
[TBL] [Abstract][Full Text] [Related]
17. A panel of miRNAs as prognostic markers for African-American patients with triple negative breast cancer.
Turkistani S; Sugita BM; Fadda P; Marchi R; Afsari A; Naab T; Apprey V; Copeland RL; Campbell MC; Cavalli LR; Kanaan Y
BMC Cancer; 2021 Jul; 21(1):861. PubMed ID: 34315420
[TBL] [Abstract][Full Text] [Related]
18. The microRNAs miR-200b-3p and miR-429-5p target the LIMK1/CFL1 pathway to inhibit growth and motility of breast cancer cells.
Li D; Wang H; Song H; Xu H; Zhao B; Wu C; Hu J; Wu T; Xie D; Zhao J; Shen Q; Fang L
Oncotarget; 2017 Oct; 8(49):85276-85289. PubMed ID: 29156719
[TBL] [Abstract][Full Text] [Related]
19. Identification of dysregulated miRNAs in triple negative breast cancer: A meta-analysis approach.
Naorem LD; Muthaiyan M; Venkatesan A
J Cell Physiol; 2019 Jul; 234(7):11768-11779. PubMed ID: 30488443
[TBL] [Abstract][Full Text] [Related]
20. Discovering the Biological Significance and Therapeutic Potential of miR-29b-3p in Triple-Negative Breast Cancer.
Jurj A; Zanoaga O; Raduly L; Morhan V; Papi Z; Ciocan C; Pop LA; Berindan-Neagoe I; Braicu C
Int J Mol Sci; 2023 Mar; 24(5):. PubMed ID: 36902482
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]